FRANKFURT (Reuters) -Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial. The Swiss drugmaker said the Phase III trial data on treating the condition known as IgA nephropathy would support a request in 2026 for traditional […]
Health
Novartis’ Fabhalta slows progression of rare kidney disease in trial
Audio By Carbonatix
FRANKFURT (Reuters) -Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease under final results of a late-stage trial.
The Swiss drugmaker said the Phase III trial data on treating the condition known as IgA nephropathy would support a request in 2026 for traditional U.S. regulatory market approval.
(Reporting by Ludwig Burger; Editing by Kim Coghill)